<VariationArchive RecordType="classified" VariationID="470218" VariationName="NC_000019.10:g.(?_11018951)_(11030899_?)del" VariationType="Deletion" Accession="VCV000470218" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2022-04-25" DateCreated="2017-12-26" MostRecentSubmission="2017-12-26">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="469448" VariationID="470218">
      <GeneList>
        <Gene Symbol="SMARCA4" FullName="SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4" GeneID="6597" HGNC_ID="HGNC:11100" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>19p13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="10961030" stop="11062273" display_start="10961030" display_stop="11062273" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="11071597" stop="11172957" display_start="11071597" display_stop="11172957" Strand="+" />
          </Location>
          <OMIM>603254</OMIM>
          <Haploinsufficiency last_evaluated="2013-09-04" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=SMARCA4">Some evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2013-09-04" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=SMARCA4">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NC_000019.10:g.(?_11018951)_(11030899_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>19p13.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" innerStart="11018951" innerStop="11030899" display_start="11018951" display_stop="11030899" variantLength="11949" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" innerStart="11129627" innerStop="11141575" display_start="11129627" display_stop="11141575" variantLength="11949" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000019.10" sequenceAccession="NC_000019" sequenceVersion="10" change="g.(?_11018951)_(11030899_?)del" Assembly="GRCh38">
            <Expression>NC_000019.10:g.(?_11018951)_(11030899_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000019.9" sequenceAccession="NC_000019" sequenceVersion="9" change="g.(?_11129627)_(11141575_?)del" Assembly="GRCh37">
            <Expression>NC_000019.9:g.(?_11129627)_(11141575_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000019.10:g.(?_11018951)_(11030899_?)del AND Rhabdoid tumor predisposition syndrome 2" Accession="RCV000550921" Version="1">
        <ClassifiedConditionList TraitSetID="1816">
          <ClassifiedCondition DB="MedGen" ID="C2750074">Rhabdoid tumor predisposition syndrome 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2017-03-14" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2017-03-14" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2017-12-26" MostRecentSubmission="2017-12-26">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="1816" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6949" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Rhabdoid tumor predisposition syndrome 2</ElementValue>
                <XRef ID="Rhabdoid+tumor+predisposition+syndrome+2/9252" DB="Genetic Alliance" />
                <XRef ID="MONDO:0013224" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">RTPS2</ElementValue>
                <XRef Type="MIM" ID="613325" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Rhabdoid tumor predisposition syndrome (RTPS) is characterized by a markedly increased risk of developing rhabdoid tumors â€“ rare and highly aggressive malignant tumors occurring predominantly in infants and children younger than age three years. Rhabdoid tumors can occur in almost any anatomic location, commonly in the central nervous system (i.e., atypical teratoid/rhabdoid tumor [AT/RT]); more than 50% occur in the cerebellum. Other common locations include extracranial extrarenal malignant rhabdoid tumors (e.g., rhabdoid tumors of the head and neck, paravertebral muscles, liver, bladder, mediastinum, retroperitoneum, pelvis, and heart) (eMRT), rhabdoid tumor of the kidney (RTK), and possibly small-cell carcinoma of the ovary (hypercalcemic type). Individuals with RTPS typically present before age 12 months with synchronous tumors that exhibit aggressive clinical behavior.</Attribute>
                <XRef ID="NBK469816" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="practice guideline" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29215836</ID>
                <ID Source="BookShelf">NBK469816</ID>
              </Citation>
              <XRef ID="231108" DB="Orphanet" />
              <XRef ID="69077" DB="Orphanet" />
              <XRef ID="C2750074" DB="MedGen" />
              <XRef ID="MONDO:0013224" DB="MONDO" />
              <XRef Type="MIM" ID="613325" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1240463" SubmissionDate="2017-10-05" DateLastUpdated="2017-12-26" DateCreated="2017-12-26">
        <ClinVarSubmissionID localKey="1572866|MedGen:C2750074" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000647924" DateUpdated="2017-12-26" DateCreated="2017-12-26" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-03-14">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment Type="public">This variant is an out-of-frame deletion of the genomic region encompassing exons 17-25 of the SMARCA4 gene. This creates a premature translational stop signal and is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in SMARCA4 are known to be pathogenic (PMID: 24658001, 24658002). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SMARCA4" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000019.9:g.(?_11129627)_(11141575_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C2750074" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB3109251</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1240463" TraitType="Disease" MappingType="XRef" MappingValue="C2750074" MappingRef="MedGen">
        <MedGen CUI="C2750074" Name="Rhabdoid tumor predisposition syndrome 2" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>